FY2022 EPS Estimates for Biohaven Pharmaceutical Holding Company Ltd. Cut by Cantor Fitzgerald (NYSE:BHVN)

Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVNGet Rating) – Investment analysts at Cantor Fitzgerald lowered their FY2022 earnings per share (EPS) estimates for shares of Biohaven Pharmaceutical in a note issued to investors on Wednesday, May 11th. Cantor Fitzgerald analyst C. Duncan now expects that the company will earn ($9.91) per share for the year, down from their prior estimate of ($6.85). Cantor Fitzgerald currently has a “Neutral” rating on the stock.

Biohaven Pharmaceutical (NYSE:BHVNGet Rating) last posted its earnings results on Tuesday, May 10th. The company reported ($2.97) EPS for the quarter, missing the consensus estimate of ($2.52) by ($0.45). During the same period in the previous year, the company earned ($4.21) EPS.

Other equities analysts have also issued reports about the company. Morgan Stanley reduced their target price on Biohaven Pharmaceutical from $148.00 to $146.00 and set an “equal weight” rating for the company in a report on Wednesday, April 6th. HC Wainwright lowered Biohaven Pharmaceutical from a “buy” rating to a “neutral” rating in a report on Wednesday. Mizuho boosted their target price on Biohaven Pharmaceutical from $144.00 to $154.00 and gave the company a “buy” rating in a research note on Thursday, March 3rd. Finally, SVB Leerink lowered Biohaven Pharmaceutical from an “outperform” rating to a “market perform” rating and set a $150.00 target price on the stock. in a research note on Wednesday. Six equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, Biohaven Pharmaceutical currently has an average rating of “Hold” and an average price target of $152.36.

BHVN stock opened at $140.60 on Friday. The business has a 50 day moving average of $112.68 and a 200-day moving average of $121.20. Biohaven Pharmaceutical has a 12-month low of $65.24 and a 12-month high of $151.51.

In other Biohaven Pharmaceutical news, CAO George C. Clark sold 4,200 shares of Biohaven Pharmaceutical stock in a transaction on Tuesday, May 10th. The stock was sold at an average price of $141.50, for a total value of $594,300.00. Following the completion of the sale, the chief accounting officer now owns 4,065 shares of the company’s stock, valued at approximately $575,197.50. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 12.40% of the stock is currently owned by company insiders.

Several hedge funds have recently made changes to their positions in the company. National Bank of Canada FI purchased a new position in Biohaven Pharmaceutical during the fourth quarter valued at $28,000. Elkhorn Partners Limited Partnership purchased a new position in Biohaven Pharmaceutical during the fourth quarter valued at $48,000. US Bancorp DE grew its stake in Biohaven Pharmaceutical by 19.1% during the first quarter. US Bancorp DE now owns 586 shares of the company’s stock valued at $70,000 after acquiring an additional 94 shares in the last quarter. Harbor Investment Advisory LLC grew its stake in Biohaven Pharmaceutical by 25.4% during the fourth quarter. Harbor Investment Advisory LLC now owns 587 shares of the company’s stock valued at $81,000 after acquiring an additional 119 shares in the last quarter. Finally, Washington Trust Advisors Inc. grew its stake in Biohaven Pharmaceutical by 24.6% during the first quarter. Washington Trust Advisors Inc. now owns 810 shares of the company’s stock valued at $96,000 after acquiring an additional 160 shares in the last quarter. Hedge funds and other institutional investors own 88.03% of the company’s stock.

About Biohaven Pharmaceutical (Get Rating)

Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications.

Featured Stories

Earnings History and Estimates for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.